CoChat
Sign Up
Cited by 45Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsMultiple Sclerosis Research Studies

Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders

Open access
Golde, Todd E.·2019·Neuron
DOI 10.1016/j.neuron.2019.02.027PMC PMC6594693
Open this paper in CoChat — free accountOpen PDF

Abstract

Immunoproteostasis is a term used to reflect interactions between the immune system and the proteinopathies that are presumptive "triggers" of many neurodegenerative disorders. The study of immunoproteostasis is bolstered by several observations. Mutations or rare variants in genes expressed in microglial cells, known to regulate immune functions, or both can cause, or alter risk for, various neurodegenerative disorders. Additionally, genetic association studies identify numerous loci harboring genes that encode proteins of known immune function that alter risk of developing Alzheimer's disease (AD) and other neurodegenerative proteinopathies. Further, preclinical studies reveal beneficial effects and liabilities of manipulating immune pathways in various neurodegenerative disease models. Although there are concerns that manipulation of the immune system may cause more harm than good, there is considerable interest in developing immune modulatory therapies for neurodegenerative disorders. Herein, I highlight the promise and challenges of harnessing immunoproteostasis to treat neurodegenerative proteinopathies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuron.2019.02.027

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 108

  1. Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, Yeromin AV, Scarfone VM, Marsh SE, Fimbres C, (2017). iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases. Neuron 94, 278– 293 e279. 28426964 PMC5482419
  2. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ, (2003). Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289, 2819– 2826. 12783912
  3. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, (2000). Inflammation and Alzheimer’s disease. Neurobiol Aging 21, 383– 421. 10858586 PMC3887148
  4. Arrant AE, Filiano AJ, Patel AR, Hoffmann MQ, Boyle NR, Kashyap SN, Onyilo VC, Young AH, and Roberson ED (2018). Reduction of microglial progranulin does not exacerbate pathology or behavioral deficits in neuronal progranulin-insufficient mice. Neurobiol Dis 124, 152– 162. 30448285 PMC6363848
  5. Ayers JI, Fromholt S, Sinyavskaya O, Siemienski Z, Rosario AM, Li A, Crosby KW, Cruz PE, DiNunno NM, Janus C, (2014). Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice. Mol Ther PMC4426802 25228069
  6. Barrow AD, and Trowsdale J (2006). You say ITAM and I say ITIM, let’s call the whole thing off: the ambiguity of immunoreceptor signalling. Eur J Immunol 36, 1646– 1653. 16783855
  7. Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, (2017). The DIAN-TU Next Generation Alzheimer’s prevention trial: Adaptive design and disease progression model. Alzheimers Dement 13, 8– 19. 27583651 PMC5218895
  8. Berry BJ, Smith AST, Young JE, and Mack DL (2018). Advances and Current Challenges Associated with the Use of Human Induced Pluripotent Stem Cells in Modeling Neurodegenerative Disease. Cells Tissues Organs, 1– 19. 30300891
  9. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, (2011). Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimers Dement 7, 402– 411. 21784351 PMC3149804
  10. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, and Anthony JC (1994). Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology 44, 227– 232. 8309563
  11. Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, and Saunders AM (1995). Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 16, 523– 530. 8544901
  12. Chakrabarty P, Ceballos-Diaz C, Lin WL, Beccard A, Jansen-West K, McFarland NR, Janus C, Dickson D, Das P, and Golde TE (2011). Interferon-gamma induces progressive nigrostriatal degeneration and basal ganglia calcification. Nat Neurosci 14, 694– 696. 21572432 PMC3780582
  13. Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, (2015). IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85, 519– 533. 25619653 PMC4320003
  14. Chang D, Nalls MA, Hallgrimsdottir IB, Hunkapiller J, van der Brug M, Cai F, International Parkinson’s Disease Genomics, C., andMe Research, T., Kerchner GA, Ayalon G, (2017). A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. Nat Genet 49, 1511– 1516. 28892059 PMC5812477
  15. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, (2006). Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920– 924. 16862115
  16. Czirr E, and Wyss-Coray T (2012). The immunology of neurodegeneration. J Clin Invest 122, 1156– 1163. 22466657 PMC3315444
  17. de Jong D, Jansen R, Hoefnagels W, Jellesma-Eggenkamp M, Verbeek M, Borm G, and Kremer B (2008). No effect of one-year treatment with indomethacin on Alzheimer’s disease progression: a randomized controlled trial. PLoS One 3, e1475. 18213383 PMC2194921
  18. Delabar J-M, Goldgaber D, Lamour Y, Nicole A, Huret J-L, de Grouchy J, Brown P, Gajdusek DC, and Sinet P-M (1987). ß amyloid gene duplication in Alzheimer’s disease and karyotypically normal Down syndrome. Science 235, 1390– 1392. 2950593
  19. Douvaras P, Sun B, Wang M, Kruglikov I, Lallos G, Zimmer M, Terrenoire C, Zhang B, Gandy S, Schadt E, (2017). Directed Differentiation of Human Pluripotent Stem Cells to Microglia. Stem Cell Reports 8, 1516– 1524. 28528700 PMC5470097
  20. Edison P, Donat CK, and Sastre M (2018). In vivo Imaging of Glial Activation in Alzheimer’s Disease. Front Neurol 9, 625. 30131755 PMC6090997
  21. Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, (2018). Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease. N Engl J Med 378, 1691– 1703. 29719179 PMC6776074
  22. Eikelenboom P, Rozemuller JM, and van Muiswinkel FL (1998). Inflammation and Alzheimer’s disease: relationships between pathogenic mechanisms and clinical expression. Exp Neurol 154, 89– 98. 9875271
  23. Erny D, Hrabe de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, Keren-Shaul H, Mahlakoiv T, Jakobshagen K, Buch T, (2015). Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 18, 965– 977. 26030851 PMC5528863
  24. Filiano AJ, Martens LH, Young AH, Warmus BA, Zhou P, Diaz-Ramirez G, Jiao J, Zhang Z, Huang EJ, Gao FB, (2013). Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci 33, 5352– 5361. 23516300 PMC3740510
  25. Filipello F, Morini R, Corradini I, Zerbi V, Canzi A, Michalski B, Erreni M, Markicevic M, Starvaggi-Cucuzza C, Otero K, (2018). The Microglial Innate Immune Receptor TREM2 Is Required for Synapse Elimination and Normal Brain Connectivity. Immunity 48, 979– 991 e978. 29752066
  26. Frei R, Steinle J, Birchler T, Loeliger S, Roduit C, Steinhoff D, Seibl R, Buchner K, Seger R, Reith W, (2010). MHC class II molecules enhance Toll-like receptor mediated innate immune responses. PLoS One 5, e8808. 20098705 PMC2808354
  27. Golde TE (2016). Overcoming translational barriers impeding development of Alzheimer’s disease modifying therapies. J Neurochem 139 Suppl 2, 224– 236. 27145445 PMC6816258
  28. Golde TE, Borchelt DR, Giasson BI, and Lewis J (2013). Thinking laterally about neurodegenerative proteinopathies. J Clin Invest 123, 1847– 1855. 23635781 PMC3635732
  29. Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, and Mrak RE (1998). Glial-neuronal interactions in Alzheimer’s disease: the potential role of a ‘cytokine cycle’ in disease progression. Brain Pathol 8, 65– 72. 9458167 PMC8098321
  30. Group A-FR (2015). Follow-up evaluation of cognitive function in the randomized Alzheimer’s Disease Anti-inflammatory Prevention Trial and its Follow-up Study. Alzheimers Dement 11, 216– 225 e211. 25022541 PMC4287453
  31. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, (2013). TREM2 variants in Alzheimer’s disease. N Engl J Med 368, 117– 127. 23150934 PMC3631573
  32. Haenseler W, Sansom SN, Buchrieser J, Newey SE, Moore CS, Nicholls FJ, Chintawar S, Schnell C, Antel JP, Allen ND, (2017). A Highly Efficient Human Pluripotent Stem Cell Microglia Model Displays a Neuronal-Co-culture-Specific Expression Profile and Inflammatory Response. Stem Cell Reports 8, 1727– 1742. 28591653 PMC5470330
  33. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, (2010). Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet 42, 781– 785. 20711177 PMC2930111
  34. Harach T, Marungruang N, Duthilleul N, Cheatham V, Mc Coy KD, Frisoni G, Neher JJ, Fak F, Jucker M, Lasser T, (2017). Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci Rep 7, 41802. 28176819 PMC5297247
  35. Hardy J, and Selkoe DJ (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. science 297, 353– 356. 12130773
  36. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, (2015). Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14, 388– 405. 25792098 PMC5909703
  37. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, (2013). NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 493, 674– 678. 23254930 PMC3812809
  38. Hill-Burns EM, Factor SA, Zabetian CP, Thomson G, and Payami H (2011). Evidence for more than one Parkinson’s disease-associated variant within the HLA region. PLoS One 6, e27109. 22096524 PMC3212531
  39. Huang KL, Marcora E, Pimenova AA, Di Narzo AF, Kapoor M, Jin SC, Harari O, Bertelsen S, Fairfax BP, Czajkowski J, (2017). A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease. Nat Neurosci 20, 1052– 1061. 28628103 PMC5759334
  40. International Genomics of Alzheimer’s Disease, C. (2015). Convergent genetic and expression data implicate immunity in Alzheimer’s disease. Alzheimers Dement 11, 658– 671. 25533204 PMC4672734
  41. Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, (2016). A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539– 547. 27371494 PMC4970664
  42. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, and Gordon MN (2002). Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22, 2246– 2254. 11896164 PMC6758281
  43. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, (2013). Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368, 107– 116. 23150908 PMC3677583
  44. Kao AW, McKay A, Singh PP, Brunet A, and Huang EJ (2017). Progranulin, lysosomal regulation and neurodegenerative disease. Nat Rev Neurosci 18, 325– 333. 28435163 PMC6040832
  45. Korvatska O, Leverenz JB, Jayadev S, McMillan P, Kurtz I, Guo X, Rumbaugh M, Matsushita M, Girirajan S, Dorschner MO, (2015). R47H Variant of TREM2 Associated With Alzheimer Disease in a Large Late-Onset Family: Clinical, Genetic, and Neuropathological Study. JAMA Neurol 72, 920– 927. 26076170 PMC4825672
  46. Koyama A, O’Brien J, Weuve J, Blacker D, Metti AL, and Yaffe K (2013). The role of peripheral inflammatory markers in dementia and Alzheimer’s disease: a meta-analysis. J Gerontol A Biol Sci Med Sci 68, 433– 440. 22982688 PMC3693673
  47. Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, (2005). Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 11, 545– 550. 15834426
  48. Labzin LI, Heneka MT, and Latz E (2018). Innate Immunity and Neurodegeneration. Annu Rev Med 69, 437– 449. 29106805
  49. Lambert JC, Grenier-Boley B, Chouraki V, Heath S, Zelenika D, Fievet N, Hannequin D, Pasquier F, Hanon O, Brice A, (2010). Implication of the immune system in Alzheimer’s disease: evidence from genome-wide pathway analysis. J Alzheimers Dis 20, 1107– 1118. 20413860
  50. Lee CYD, Daggett A, Gu X, Jiang LL, Langfelder P, Li X, Wang N, Zhao Y, Park CS, Cooper Y, (2018). Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer’s Disease Models. Neuron 97, 1032– 1048 e1035. 29518357 PMC5927822
  51. Lessard CB, Malnik SL, Zhou Y, Ladd TB, Cruz PE, Ran Y, Mahan TE, Chakrabaty P, Holtzman DM, Ulrich JD, (2018). High-affinity interactions and signal transduction between Abeta oligomers and TREM2. EMBO Mol Med 10. PMC6220267 30341064
  52. Liang Y, Buckley TR, Tu L, Langdon SD, and Tedder TF (2001). Structural organization of the human MS4A gene cluster on Chromosome 11q12. Immunogenetics 53, 357– 368. 11486273
  53. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, (2000). Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci 20, 5709– 5714. 10908610 PMC6772529
  54. Linnartz B, and Neumann H (2013). Microglial activatory (immunoreceptor tyrosine-based activation motif)- and inhibitory (immunoreceptor tyrosine-based inhibition motif)-signaling receptors for recognition of the neuronal glycocalyx. Glia 61, 37– 46. 22615186
  55. Liu D, Cao B, Zhao Y, Huang H, McIntyre RS, Rosenblat JD, and Zhou H (2018). Soluble TREM2 changes during the clinical course of Alzheimer’s disease: A meta-analysis. Neurosci Lett 686, 10– 16. 30171911
  56. Malle E, and De Beer FC (1996). Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 26, 427– 435. 8817153
  57. Mann DM (1988). Alzheimer’s disease and Down’s syndrome. Histopathology 13, 125– 137. 2971602
  58. Marsh SE, Abud EM, Lakatos A, Karimzadeh A, Yeung ST, Davtyan H, Fote GM, Lau L, Weinger JG, Lane TE, (2016). The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A 113, E1316– 1325. 26884167 PMC4780638
  59. Martens LH, Zhang J, Barmada SJ, Zhou P, Kamiya S, Sun B, Min SW, Gan L, Finkbeiner S, Huang EJ, (2012). Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Invest 122, 3955– 3959. 23041626 PMC3484443
  60. Martinez-Muriana A, Mancuso R, Francos-Quijorna I, Olmos-Alonso A, Osta R, Perry VH, Navarro X, Gomez-Nicola D, and Lopez-Vales R (2016). CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves. Sci Rep 6, 25663. 27174644 PMC4865981
  61. Masgrau R, Guaza C, Ransohoff RM, and Galea E (2017). Should We Stop Saying ‘Glia’ and ‘Neuroinflammation’? Trends Mol Med 23, 486– 500. 28499701
  62. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, and Beyreuther K (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82, 4245– 4249. 3159021 PMC397973
  63. McGeer PL, Rogers J, and McGeer EG (1994). Neuroimmune mechanisms in Alzheimer disease pathogenesis [see comments]. [Review]. Alzheimer Disease & Associated Disorders 8, 149– 158. 7986484
  64. McGeer PL, Schulzer M, and McGeer EG (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies [see comments]. Neurology 47, 425– 432. 8757015
  65. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O’Connor PW, (2003). A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348, 15– 23. 12510038
  66. Minter MR, Hinterleitner R, Meisel M, Zhang C, Leone V, Zhang X, Oyler-Castrillo P, Zhang X, Musch MW, Shen X, (2017). Antibiotic-induced perturbations in microbial diversity during post-natal development alters amyloid pathology in an aged APPSWE/PS1DeltaE9 murine model of Alzheimer’s disease. Sci Rep 7, 10411. 28874832 PMC5585265
  67. Mitsui J, Matsukawa T, Ishiura H, Higasa K, Yoshimura J, Saito TL, Ahsan B, Takahashi Y, Goto J, Iwata A, (2012). CSF1R mutations identified in three families with autosomal dominantly inherited leukoencephalopathy. Am J Med Genet B Neuropsychiatr Genet 159B, 951– 957. 23038421
  68. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, (1999). Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130, 478– 486. 10075615
  69. Nataf S, Anginot A, Vuaillat C, Malaval L, Fodil N, Chereul E, Langlois JB, Dumontel C, Cavillon G, Confavreux C, (2005). Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. Am J Pathol 166, 275– 286. 15632019 PMC1602283
  70. Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P, Subramanian N, Bunney TD, Baxendale RW, Martins MS, (2012). Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 366, 330– 338. 22236196 PMC3298368
  71. Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, (2017). A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther 9, 95. 29221491 PMC5723032
  72. Otero K, Shinohara M, Zhao H, Cella M, Gilfillan S, Colucci A, Faccio R, Ross FP, Teitelbaum SL, Takayanagi H, (2012). TREM2 and beta-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol 188, 2612– 2621. 22312126 PMC3732181
  73. Paloneva J, Autti T, Hakola P, and Haltia MJ (1993). Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL) 20301376
  74. Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A, (2002). Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 71, 656– 662. 12080485 PMC379202
  75. Perry VH, and Holmes C (2014). Microglial priming in neurodegenerative disease. Nat Rev Neurol 10, 217– 224. 24638131
  76. Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, and Cruchaga C (2016). Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131, 925– 933. 26754641 PMC4867123
  77. Prinz M, and Priller J (2017). The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci 20, 136– 144. 28092660
  78. Ransohoff RM (2016). A polarizing question: do M1 and M2 microglia exist? Nat Neurosci 19, 987– 991. 27459405
  79. Rauchmann BS, Schneider-Axmann T, Alexopoulos P, Perneczky R, and Alzheimer’s Disease Neuroimaging, I. (2018). CSF soluble TREM2 as a measure of immune response along the Alzheimer’s disease continuum. Neurobiol Aging 74, 182– 190. 30458365 PMC6331262
  80. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, and Tariot PN (2011). Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 26 Suppl 3, 321– 329. 21971471 PMC3343739
  81. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC, and Rofecoxib Protocol 091 Study, G. (2004). Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 62, 66– 71. 14718699
  82. Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BN, Wang LS, Valladares O, Lin CF, Larson EB, Graff-Radford NR, (2013). Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4,and the risk of late-onset Alzheimer disease in African Americans. JAMA 309, 1483– 1492. 23571587 PMC3667653
  83. Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, and McGeer P (1996). Inflammation and Alzheimer’s disease pathogenesis. Neurobiol Aging 17, 681– 686. 8892340
  84. Sack GH Jr. (2018). Serum amyloid A - a review. Mol Med 24, 46. 30165816 PMC6117975
  85. Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, (2016). Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease. Cell 167, 1469– 1480 e1412. 27912057 PMC5718049
  86. Schlepckow K, Kleinberger G, Fukumori A, Feederle R, Lichtenthaler SF, Steiner H, and Haass C (2017). An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol Med 9, 1356– 1365. 28855300 PMC5623859
  87. Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, (2016). The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature 537, 50– 56. 27582220
  88. Shatz CJ (2009). MHC class I: an unexpected role in neuronal plasticity. Neuron 64, 40– 45. 19840547 PMC2773547
  89. Siddiqui SS, Springer SA, Verhagen A, Sundaramurthy V, Alisson-Silva F, Jiang W, Ghosh P, and Varki A (2017). The Alzheimer’s disease-protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool. J Biol Chem 292, 15312– 15320. 28747436 PMC5602391
  90. Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, Gomez-Marin C, Aneas I, Credidio FL, Sobreira DR, Wasserman NF, (2014). Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature 507, 371– 375. 24646999 PMC4113484
  91. Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, Rossi G, Pareyson D, Mole SE, Staropoli JF, (2012). Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet 90, 1102– 1107. 22608501 PMC3370276
  92. Soininen H, West C, Robbins J, and Niculescu L (2007). Long-term efficacy and safety of celecoxib in Alzheimer’s disease. Dement Geriatr Cogn Disord 23, 8– 21. 17068392
  93. Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, and Colonna M (2018). Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med 215, 745– 760. 29321225 PMC5839761
  94. Soragna D, Papi L, Ratti MT, Sestini R, Tupler R, and Montalbetti L (2003). An Italian family affected by Nasu-Hakola disease with a novel genetic mutation in the TREM2 gene. J Neurol Neurosurg Psychiatry 74, 825– 826. PMC1738498 12754369
  95. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, and Aisen P (2014). The A4 study: stopping AD before symptoms begin? Sci Transl Med 6, 228fs213. PMC4049292 24648338
  96. Stabile C, Taglia I, Battisti C, Bianchi S, and Federico A (2016). Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS): update on molecular genetics. Neurol Sci 37, 1565– 1569. 27338940
  97. Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C, (2016a). Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8, 369ra178. PMC5385711 27974666
  98. Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, Fortea J, Lleo A, Blesa R, Gispert JD, (2016b). sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer’s disease and associate with neuronal injury markers. EMBO Mol Med 8, 466– 476. 26941262 PMC5120370
  99. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, and Herrmann N (2010). A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry 68, 930– 941. 20692646
  100. Takata K, Kozaki T, Lee CZW, Thion MS, Otsuka M, Lim S, Utami KH, Fidan K, Park DS, Malleret B, (2017). Induced-Pluripotent-Stem-Cell-Derived Primitive Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage Differentiation and Function. Immunity 47, 183– 198 e186. 28723550
  101. Tung YCL, Yeo GSH, O’Rahilly S, and Coll AP (2014). Obesity and FTO: Changing Focus at a Complex Locus. Cell Metab 20, 710– 718. 25448700
  102. Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, Vieira-Saecker A, Schwartz S, Santarelli F, Kummer MP, (2017). Microglia-derived ASC specks cross-seed amyloid-beta in Alzheimer’s disease. Nature 552, 355– 361. 29293211
  103. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, and Chartash EK (2003). Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48, 35– 45. 12528101
  104. Wissemann WT, Hill-Burns EM, Zabetian CP, Factor SA, Patsopoulos N, Hoglund B, Holcomb C, Donahue RJ, Thomson G, Erlich H, (2013). Association of Parkinson disease with structural and regulatory variants in the HLA region. Am J Hum Genet 93, 984– 993. 24183452 PMC3824116
  105. Zandi PP, and Breitner JC (2001). Do NSAIDs prevent Alzheimer’s disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 22, 811– 817. 11754987
  106. Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MS, Li G, (2016). Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron 89, 37– 53. 26687838 PMC4707064
  107. Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Pina-Crespo JC, Zhang M, (2018). TREM2 Is a Receptor for beta-Amyloid that Mediates Microglial Function. Neuron 97, 1023– 1031 e1027. 29518356 PMC5889092
  108. Zhou Q, Lee GS, Brady J, Datta S, Katan M, Sheikh A, Martins MS, Bunney TD, Santich BH, Moir S, (2012). A hypermorphic missense mutation in PLCG2, encoding phospholipase Cgamma2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet 91, 713– 720. 23000145 PMC3484656

Cited by

Sorted by citations

Authors
Golde, T. E.
Affiliations
University of Florida (US)
Corresponding author
Golde, Todd E.
ORCID
Golde, Todd E.
Venue
Neuron
Publisher
Elsevier BV
Published
2019-03
Volume
101
Issue
6
Pages
1003-1015
ISSN
0896-6273 (ISSN-L)
DOI
10.1016/j.neuron.2019.02.027
PMC
PMC6594693
OpenAlex
W2923523140
Cited by
45
References
45
Citations by year
2025: 3 · 2024: 2 · 2023: 7 · 2022: 19 · 2021: 5 · 2020: 7 · 2019: 2
FWCI
0.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuron (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (R01AG018454, U01AG046139, P50AG047266)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
Keywords
neurodegenerative diseases, proteinopathies, microglia, Alzheimer's disease, genetic susceptibility loci, immunomodulatory therapy, neuroinflammation, immune system manipulation
MeSH terms
Proteostasis, Alzheimer Disease, Animals, Humans, Immunoproteins, Inflammation, Microglia, Neurodegenerative Diseases, Genetic Predisposition to Disease, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review